119
A drug interaction between the alpha(2)-adrenergic agonist medetomidine and lignocaine is suspected and highlights the potential for seizures following the subcutaneous administration of relatively large doses of lignocaine under medetomidine sedation.
 seizures: Effect; subcutaneous administration of relatively large doses of lignocaine under medetomidine sedation: Treatment; lignocaine: Treatment.Drug; medetomidine: Treatment.Drug; subcutaneous: Treatment.Route; medetomidine: Combination.Drug; lignocaine: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 seizures: Effect; subcutaneous administration of relatively large doses of lignocaine under medetomidine sedation: Treatment; lignocaine: Treatment.Drug; medetomidine: Treatment.Drug; subcutaneous: Treatment.Route; medetomidine: Combination.Drug; lignocaine: Combination.Drug